Immuneering CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

6 Mar 2026

IMRX

10-K: Immuneering's Atebimetinib Advances to Phase 3 for Pancreatic Cancer

Immuneering Corporation reports positive interim Phase 2a data for atebimetinib in pancreatic cancer, initiating a Phase 3 trial, while pausing envometinib development to focus resources.

NASDAQ

20 Mar 2025

IMRX

Immuneering CORP

10-K: Immuneering Corporation Reports Full Year 2024 Results, Cites Going Concern Uncertainty

Immuneering Corporation's 2024 10-K filing reveals ongoing clinical trials, significant net losses, and substantial doubt about the company's ability to continue as a going concern.

NASDAQ

1 Mar 2024

IMRX

Immuneering CORP

10-K: Immuneering Corp. Announces Executive Compensation Changes and New Employment Agreements

Immuneering Corporation has disclosed changes to executive compensation, including salary increases, bonus adjustments, and new stock option grants, alongside new employment agreements for key personnel.